Diasorin S.p.a. · MIL:DIA
Diasorin — Merger or Acquisition (March 2016)
17 slides from Diasorin's merger presentation, Mar 30, 2016
Slide 1: Planned Acquisition of Focus Diagnostics' Product Business
Planned Acquisition of Focus Diagnostics’ Product Business 30 March 2016 The acquisition is of the Focus Diagnostics products business; it does not include certain clinical laboratories operating under that brand name which will continue to operate as part of Quest.
Slide 2: Disclaimer
Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Focus: business description
Focus: business description
Slide 4: Focus' Product Business at a glance
Focus’ Product Business at a glance Who is Focus Diagnostics Focus Diagnostics manufactures and distributes best-in-class: molecular products classic (serology) tests diagnostic solutions for emerging infectious diseases for hospitals and commercial labs worldwide Founded in 1978 and acquired by Que
Slide 5: Focus' Product Business at a glance: What Focus Diagnostics offers
Focus’ Product Business at a glance What Focus Diagnostics offers Molecular Diagnostics TM Real-time PCR assays for quantitative, qualitative and multi-analyte detection ASRs Analyte Specific Reagents (ASR) Immunoassay ELISA + IFA Type specific classic tests aid in presumptive diagnosis of HSV-1 and
Slide 6: Focus Molecular Diagnostic solutions
Focus Molecular Diagnostic solutions Integrated Cycler: SIMPLEXA TM Technology originally developed by 3M, PCR-based, enabling easy handling of molecular diagnostic testing in the labs The Integrated Cycler is: a versatile, practical laboratory instrument scalable, flexible, small and fast easily in
Slide 7: Functioning of the Integrated Cycler
Functioning of the Integrated Cycler Ease of use Set up 1. Scan Assay Barcode 2. Scan Reagent Lot 3. Scan DAD ID 4. Scan Patient ID 1 Load 1. Lift foil from wells 2. Pipette REACTION 3. Pipette specimen into 4. Re-seal wells with foil. 2 Mix into «R» well «SAMPLE» well Tear off perforated edge Run P
Slide 8: Molecular Diagnostic tests portfolio
Molecular Diagnostic tests portfolio TM / ASRs Healthcare Immuno- Infectious Respiratory Associated Genetics Vector-Borne compromised Disease Infections H1N1 (2009) BKV HSV-1 C. difficile Factor II Borrelia B. pertussis HHV-6 HSV-2 KPC Factor V Chikungunya B. parapertussis JCV Enterovirus Norovirus
Slide 9: Immunoassay ELISA tests portfolio
Immunoassay ELISA tests portfolio Infectious Immuno- Vector-Borne Disease compromised West Nile Virus Dengue 1,2,3,4 JCV HSV-1 Hantavirus HSV-2 Histoplasma Parvovirus A specialized menu of ELISA tests International Catalog US Catalog Title of acquisition Planned presentationof Focus Diagnostics’ Pro
Slide 10: Rationale and financing of the planned acquisition
Rationale and financing of the planned acquisition
Slide 11: The rationale of the planned acquisition
The rationale of the planned acquisition A perfect fit with the business expectations MOLECULAR DIAGNOSTICS: Infectious disease menu expansion It will allow DiaSorin to compete in the Molecular Diagnostics segment with a set of specialty products, a market which is experiencing rapid growth in the U
Slide 12: Sales expansion of Focus products
Sales expansion of Focus products Sales expansion of the Focus Diagnostics products leveraging the current DiaSorin global presence NORTH AMERICA MDX tests EUROPE ELISA tests ASIA PACIFIC LATIN AMERICA Planned acquisition of Focus Diagnostics’ Product Business - March 30, 2016 12
Slide 13: New DiaSorin positioning in the US market
New DiaSorin positioning in the US market MEGA ELISA tests LABS MID-SIZE REFERENCE LABS & HOSPITAL LABS Strategic positioning in the US with > 200 hospitals, many of which are the largest in the US Expansion in a new market segment SMALL SIZE LABS & PHYSICIAN OFFICE LABS from 2018 Planned acquisitio
Slide 14: Financing of the planned acquisition
Financing of the planned acquisition Financing Price of the transaction The price for the transaction is $ 300 million on a debt free cash free basis, with an agreed normalized level of trade receivables and payables Funding The cash transaction will be funded through available cash and a line of cr
Slide 15: Focus: Financials
Focus: Financials
Slide 16: Focus Products' Financials 2015
Focus Products’ Financials 2015* 2015A Financials* Revenues * ~ 80 $/mln % of US Revenues ~ 80% % of International Revenues ~ 20% EBITDA Margin * estimated in the range of 30% * financial data is unaudited Title of acquisition Planned presentationof Focus Diagnostics’ Product Business - March 30, 20
Slide 17: DiaSorin
DiaSorin The Diagnostic Specialist